LV11782B - Treatment of ovarian estrogen dependent conditions - Google Patents

Treatment of ovarian estrogen dependent conditions Download PDF

Info

Publication number
LV11782B
LV11782B LVP-96-354A LV960354A LV11782B LV 11782 B LV11782 B LV 11782B LV 960354 A LV960354 A LV 960354A LV 11782 B LV11782 B LV 11782B
Authority
LV
Latvia
Prior art keywords
antiprogestin
preparation according
treatment
estrogen
administration
Prior art date
Application number
LVP-96-354A
Other languages
English (en)
Latvian (lv)
Other versions
LV11782A (lv
Inventor
Gary D Hodgen
Robert F Williams
Daniel Grow
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of LV11782A publication Critical patent/LV11782A/xx
Publication of LV11782B publication Critical patent/LV11782B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
LVP-96-354A 1994-02-04 1996-09-03 Treatment of ovarian estrogen dependent conditions LV11782B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/191,631 US5681817A (en) 1994-02-04 1994-02-04 Treatment of ovarian estrogen dependent conditions
PCT/US1995/001479 WO1995020972A1 (en) 1994-02-04 1995-02-02 Treatment of ovarian estrogen dependent conditions

Publications (2)

Publication Number Publication Date
LV11782A LV11782A (lv) 1997-06-20
LV11782B true LV11782B (en) 1997-12-20

Family

ID=22706258

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-354A LV11782B (en) 1994-02-04 1996-09-03 Treatment of ovarian estrogen dependent conditions

Country Status (29)

Country Link
US (1) US5681817A (bg)
EP (1) EP0785792B1 (bg)
JP (1) JP3130048B2 (bg)
KR (1) KR970700507A (bg)
CN (1) CN1144486A (bg)
AP (1) AP724A (bg)
AT (1) ATE179610T1 (bg)
AU (1) AU689229B2 (bg)
BG (1) BG62238B1 (bg)
BR (1) BR9506606A (bg)
CA (1) CA2182183C (bg)
CZ (1) CZ291709B6 (bg)
DE (1) DE69509544T2 (bg)
DK (1) DK0785792T3 (bg)
ES (1) ES2132645T3 (bg)
FI (1) FI963036A0 (bg)
GR (1) GR3030164T3 (bg)
HU (1) HUT74622A (bg)
LT (1) LT4182B (bg)
LV (1) LV11782B (bg)
MD (1) MD1432C2 (bg)
NZ (1) NZ281441A (bg)
OA (1) OA10777A (bg)
PL (1) PL178273B1 (bg)
RO (1) RO117420B1 (bg)
RU (1) RU2110274C1 (bg)
SK (1) SK96296A3 (bg)
TJ (1) TJ242B (bg)
WO (1) WO1995020972A1 (bg)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1137722C (zh) * 1994-07-22 2004-02-11 汉普顿路医学院 为长期治疗方案确立基础(tonic)卵巢雌激素分泌
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
EP1029868A4 (en) 1997-10-17 2003-10-22 Mochida Pharm Co Ltd AGENT AGAINST HYSTEROMYOMAS CONTAINS DIENOGEST AS AN ACTIVE SUBSTANCE
US6703367B1 (en) 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
PT1229906E (pt) * 1999-08-31 2008-01-18 Bayer Schering Pharma Ag Mesoprogestinas para o tratamento e prevenção de distúrbios ginecológicos hormonodependentes benignos
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US6960337B2 (en) * 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
EP2316441A1 (en) * 2005-02-17 2011-05-04 Hadasit Medical Research Services And Development Bisphosphonates for treating endometriosis
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
SI3263112T1 (sl) * 2006-10-24 2020-10-30 Allergan Pharmaceuticals International Limited Sestavki in metode za zaviranje endometrijskih proliferacij
TWI455716B (zh) * 2006-10-24 2014-10-11 Repros Therapeutics Inc 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
WO2008144143A1 (en) * 2007-05-14 2008-11-27 Drugtech Corporation Endometriosis treatment
EP2197415B1 (en) * 2007-09-20 2014-03-05 Lapidot Medical Import And Marketing Ltd Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endrometriosis, adenomyosis and related disorders by mifepristone
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
KR101585221B1 (ko) 2014-02-27 2016-01-13 권희완 지압대 겸용 지압 베개
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
ATE86484T1 (de) 1987-08-08 1993-03-15 Akzo Nv Kontrazeptives implantat.
DE3744054A1 (de) 1987-12-21 1989-06-29 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
JP3112172B2 (ja) 1990-03-16 2000-11-27 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ ベノートスハップ 多嚢胞卵巣疾病の治療
US6827050B2 (en) 2001-12-21 2004-12-07 Caterpillar Inc Fluid control valve actuating system
US7283632B2 (en) 2003-09-09 2007-10-16 The Boeing Company Unauthorized access embedded software protection system

Also Published As

Publication number Publication date
JP3130048B2 (ja) 2001-01-31
RO117420B1 (ro) 2002-03-29
HUT74622A (en) 1997-01-28
GR3030164T3 (en) 1999-08-31
CA2182183C (en) 2003-09-16
PL315792A1 (en) 1996-12-09
CN1144486A (zh) 1997-03-05
HU9601969D0 (en) 1996-09-30
CZ291709B6 (cs) 2003-05-14
EP0785792A4 (bg) 1997-07-30
JPH09508418A (ja) 1997-08-26
BG62238B1 (bg) 1999-06-30
RU2110274C1 (ru) 1998-05-10
AP9600840A0 (en) 1996-07-31
BG100766A (bg) 1997-06-30
DE69509544D1 (de) 1999-06-10
FI963036A (fi) 1996-08-01
FI963036A0 (fi) 1996-08-01
AU1838695A (en) 1995-08-21
NZ281441A (en) 1999-09-29
MD1432C2 (ro) 2000-09-30
CA2182183A1 (en) 1995-08-10
AU689229B2 (en) 1998-03-26
ES2132645T3 (es) 1999-08-16
LT4182B (en) 1997-06-25
SK96296A3 (en) 1997-07-09
CZ210396A3 (en) 1997-05-14
DE69509544T2 (de) 1999-09-02
PL178273B1 (pl) 2000-03-31
US5681817A (en) 1997-10-28
MD1432B2 (en) 2000-03-31
KR970700507A (ko) 1997-02-12
EP0785792A1 (en) 1997-07-30
BR9506606A (pt) 1997-09-09
DK0785792T3 (da) 1999-10-18
OA10777A (en) 2002-12-23
WO1995020972A1 (en) 1995-08-10
ATE179610T1 (de) 1999-05-15
EP0785792B1 (en) 1999-05-06
LT96133A (en) 1997-01-27
TJ242B (en) 1999-11-24
LV11782A (lv) 1997-06-20
AP724A (en) 1999-01-18

Similar Documents

Publication Publication Date Title
US5681817A (en) Treatment of ovarian estrogen dependent conditions
Felberbaum et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
US8450299B2 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US5468736A (en) Hormone replacement therapy
Lethaby et al. An evidence-based approach to hormonal therapies for premenopausal women with fibroids
EP2392332A1 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Friedman Treatment of uterine myomas with GnRH agonists
RU2181598C2 (ru) Восстановление тонической секреции эстрогена из яичников для продолжительных схем лечения
BG66128B1 (bg) Фармацевтичен състав и използването му за терапевтичен контрол на извънматочна пролиферация на ендометриална тъкан
BG106442A (bg) Мезопрогестини (прогестерон рецептор модулатори) за лечение и профилактика на хормонозависими доброкачествени гинекологични заболявания
LT4341B (lt) Toninės kiaušidžių estrogeno sekrecijos sureguliavimas pailgintiems terapiniams režimams
AU2011203526A1 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens